In the past decade, clinical trials have contributed to rapidly advancing research, which has led to more individuals living with lung cancer exceeding the five-year survival rate than ever before. Unfortunately, this progress has not been shared equally amongst the populations facing high lung cancer burdens. That’s why the American Lung Association is expanding its work through the Awareness, Trust and Action program to educate Hispanic individuals about clinical trials and encourage them to speak with their healthcare provider about their treatment options. While progress in the early detection and treatment of the disease in recent years has increased the five-year survival rate to 26.6% nationally, this progress has not been shared equally. Hispanic individuals with lung cancer were 16% less likely to be diagnosed early, 30% more likely to not receive any treatment, and 9% less likely to survive… 

Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor. HORIZON met its co-primary endpoints: achievement of a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) score of 0 (clear) or 1 (almost clear) with a ? 2-point reduction from baseline [19.3% rocatinlimab vs. 6.6% placebo (12.8% difference, p<0.001)] and achievement of ? 75% reduction from baseline in Eczema Area and Severity Index score (EASI-75) [32.8% rocatinlimab vs. 13.7% placebo (19.1% difference, p<0.001)], both at week 24. The trial also met the revised Investigator Global Assessment (rIGA 0/1) *[1], a more stringent measure of efficacy than vIGA 0/1 based on a narrower definition of 1 (almost clear), at week 24 [16.4% rocatinlimab vs. 4.9% placebo (11.5% difference, p<0.001)]. HORIZON… 

Bakterielle Infektionen, die zu Enteritis führen, manchmal auch extraintestinale Infektionen wie Sepsis, sind weiterhin ein globales Gesundheitsproblem. Eine der Hauptursachen für Todesfälle durch Durchfallerkrankungen und extraintestinale Infektionen bei Kindern unter 5 Jahren und älteren Menschen ist eine Infektion mit Campylobacter -Bakterien, gegen die es weder einen wirksamen Impfstoff noch Medikamente gibt. Ein von der Osaka Metropolitan University geleitetes Team hat kürzlich etwas entdeckt, das ein wichtiger Schritt zur Vorbeugung, Diagnose und Behandlung einer Art von Campylobacter -Bakterien sein könnte. Forscher, darunter Professor Shinji Yamasaki und Associate Professor Noritoshi Hatanaka von der Graduate School of Veterinary Science und dem Osaka International Research Center for Infectious Diseases an der OMU, konzentrierten sich auf Campylobacter jejuni , die Bakterienart, die häufig Gastroenteritis und manchmal extraintestinale Infektionen verursacht. Gemeinsam entwickelten sie einen Antikörper, der C. jejuni identifizieren und das Wachstum der Bakterien hemmen kann.…